Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Peripheral Nervous System Diseases 5Lymphoma 5Head and Neck Neoplasms 4Breast Neoplasms 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Stomatitis 2Stomach Neoplasms 2Sarcoma 2Pain 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Malnutrition 2Wilms Tumor 1Vaso-Occlusive Crises 1Squamous Cell Carcinoma of Head and Neck 1Sarcopenia 1Recurrence 1Radiation Injuries 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Oral Complications 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Malignant mesenchymal tumor 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Glutamine × Clear all
NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡